ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Citrate in Diagnosis and Follow-up for Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00804063
Recruitment Status : Completed
First Posted : December 8, 2008
Last Update Posted : January 8, 2015
Sponsor:
Collaborator:
Kantonsspital Baselland Bruderholz
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
Glaucoma might be a mitochondria associated disease. Since citrate is a major component in mitochondrial metabolism its determination in blood might serve as a biomarker.

Condition or disease Intervention/treatment
Glaucoma Procedure: drawing blood sample

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Serum Citrate in Diagnosis and Follow-up for Glaucoma
Study Start Date : December 2008
Actual Primary Completion Date : December 2012
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Group/Cohort Intervention/treatment
1
glaucoma patients
Procedure: drawing blood sample
fasting blood sample
2
non-glaucoma controls
Procedure: drawing blood sample
fasting blood sample



Primary Outcome Measures :
  1. serum citrate level [ Time Frame: 1 ]

Secondary Outcome Measures :
  1. urine citrate [ Time Frame: 1 ]

Biospecimen Retention:   Samples With DNA
blood, urine, serum, aqueous


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
tertiary university center
Criteria

Inclusion Criteria:

  • age> 18 years
  • glaucoma

Exclusion Criteria:

  • Active ocular inflammation
  • Ocular Hypertension
  • Nephropathy
  • Alcohol-, Drug abuse
  • Mitochondriopathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00804063


Locations
Switzerland
University Hospital Basel
Basel, Basel-Stadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Kantonsspital Baselland Bruderholz
Investigators
Principal Investigator: David Goldblum, MD University Hospital, Basel, Switzerland
Study Chair: Josef Flammer, MD University Hospital, Basel, Switzerland
Study Director: Selim Orguel, MD University Hospital, Basel, Switzerland
Principal Investigator: Stephan Fraenkl, MD University Hospital, Basel, Switzerland
Principal Investigator: Fabrizio Branca, MD University Basel

Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00804063     History of Changes
Other Study ID Numbers: EK 325/08
First Posted: December 8, 2008    Key Record Dates
Last Update Posted: January 8, 2015
Last Verified: January 2015

Keywords provided by University Hospital, Basel, Switzerland:
glaucoma
citrate

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Citric Acid
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action